ALS ACT (Accelerated Therapeutics)
Request for Proposals: Early phase clinical development of novel, high-potential treatments for people with ALSIn The Media
ALS Finding a Cure (ALS FAC), the ALS Association (ALSA) and the Northeast ALS Consortium (NEALS) are pleased to announce a call for phase I/II clinical trial applications for novel, high-potential treatments in Amyotrophic Lateral Sclerosis – ALS ACT. The call for clinical study proposals is intended for academic-industry partnerships, including pharmaceutical, biotherapeutic/biotechnology companies, academic members of NEALS, and ALS scientists throughout the world. Read the full press release below.
Clinical Trial: ALS Association and ALS Finding a Cure® Supported Phase II RNS60 Trial is Now EnrollingIn The Media
The clinical trial to test RNS60, a new compound for the treatment of ALS, which was supported in part from a $1.0 million grant through the ALS ACT initiative funded by The ALS Association and ALS Finding A Cure®, is now actively enrolling. This randomized placebo-controlled phase II study is being run by the IRCCS Mario Negri Institute for Pharmacological Research in Milan and the ALS Center of the Maggiore University Hospital in Novara Italy. We are happy to report that the first patient was dosed in mid-July 2017.
What Are The Unmet Needs In ALS Research?In The Media
At AAN 2017, Merit Cudkowicz, MD, MSc., Chief of Neurology, Massachusetts General Hospital explained that ALS has changed dramatically in the last decade. "There's so much more hope and more knowledge about what might be happening," Cudkowicz told MD Magazine. She said that there are new foundations including the ALS Finding A Cure that aims to accelerate finding a cure. Also, according to Cudkowicz, the "Ice Bucket Challenge" really made a huge difference in awareness; people across the globe now know what ALS is.